{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.8","upperLimit":"31.7","value":"14.5"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"8.0","value":"4.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Adenoid Cystic Carcinoma"},{"description":"Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Non Adenoid Cystic Carcinoma"}],"paramType":"MEDIAN","populationDescription":"There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}